Macrogen, Inc. (KOSDAQ:038290)
15,450
+310 (2.05%)
Nov 20, 2025, 3:30 PM KST
Macrogen Revenue
Macrogen had revenue of 48.99B KRW in the quarter ending June 30, 2025, with 62.40% growth. This brings the company's revenue in the last twelve months to 163.92B, up 25.11% year-over-year. In the year 2024, Macrogen had annual revenue of 135.78B with 2.24% growth.
Revenue (ttm)
163.92B
Revenue Growth
+25.11%
P/S Ratio
1.00
Revenue / Employee
327.84M
Employees
500
Market Cap
164.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 135.78B | 2.97B | 2.24% |
| Dec 31, 2023 | 132.80B | -5.81B | -4.19% |
| Dec 31, 2022 | 138.62B | 9.44B | 7.31% |
| Dec 31, 2021 | 129.17B | 16.57B | 14.72% |
| Dec 31, 2020 | 112.60B | 9.79B | 9.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 620.28B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |